Table 2 Mortality of AGIB patients based on the LS-SVMR model in overall and subgroups analysis
LS-SVMR score | Mortality | |
|---|---|---|
Training cohort | Validation cohort | |
Overall AGIB patients | ||
<0.084 | 0.38% (4/1056) | 0.48% (5/1044) |
0.084–0.160 (gray zone) | 2.22% (2/90) | 6.82% (6/88) |
>0.160 | 64.37% (56/87) | 64.71% (66/102) |
Patients with variceal bleeding | ||
<0.080 | 0.16% (1/643) | 0.15% (1/646) |
0.080–0.082 (gray zone) | 25.00% (1/4) | 0% (0/5) |
>0.082 | 19.10% (17/89) | 20.95% (22/105) |
Patients who underwent endoscopic treatment | ||
<0.080 | 0.33% (2/615) | 0.16% (1/609) |
0.080–0.081 (gray zone) | 50.00% (1/2) | 0% (0/3) |
>0.081 | 24.18% (22/91) | 19.15% (18/94) |
Patients who received pharmacological treatment without endoscopic treatment | ||
<0.092 | 0.26% (1/385) | 1.06% (4/378) |
0.092–0.157 (gray zone) | 6.45% (2/31) | 19.23% (5/26) |
>0.157 | 72.34% (34/47) | 80.77% (42/52) |
